Categoria
Fugacin
Marchi,
Fugacin
Analoghi
Fugacin
Marchi miscela
No information avaliable
Fugacin
Formula chimica
C18H20FN3O4
Fugacin
RX link
http://www.rxlist.com/cgi/generic/oflox.htm
Fugacin
FDA foglio
Fugacin
DMS (foglio di materiale di sicurezza)
Fugacin
Sintesi di riferimento
I. Hayakava et al. US Pat. 4,382,892 (1983)
Fugacin
Peso molecolare
361.368 g/mol
Fugacin
Temperatura di fusione
250-257 oC
Fugacin
H2O Solubilita
28,3 mg / ml
Fugacin
Stato
Solid
Fugacin
LogP
1.268
Fugacin
Forme di dosaggio
Soluzione (IV iniezione); Tablet; gocce oftalmiche
Fugacin
Indicazione
Per il trattamento di infezioni (tratto respiratorio, dei reni, pelle, tessuti molli, UTI), uretrale e cervicale gonorrea.
Fugacin
Farmacologia
Ofloxacina è un chinolonico / fluorochinolone antibiotico. Ofloxacin è battericida e il suo modo di agire dipende il blocco della replicazione del DNA batterico da legarsi ad un enzima chiamato DNA girasi, che permette al untwisting necessario per replicare una doppia elica del DNA in due. In particolare il farmaco ha affinità 100 volte superiore per DNA girasi batterica rispetto a mammiferi. Ofloxacina è un ampio spettro antibiotico attivo contro i batteri sia Gram-positivi e Gram-negativi.
Fugacin
Assorbimento
Biodisponibilità di ofloxacina nella formulazione in compresse è circa del 98%
Fugacin
Tossicita
LD50 = 5450 mg / kg (per via orale nei topi)
Fugacin
Informazioni paziente
PATIENT INFORMATION
Patients should be advised:
- to drink fluids liberally;
- that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based
antacids, sucralfate or Videx�, (Didanosine), chewable/buffered tablets or the pediatric powder for
oral solution should not be taken within the two-hour period before or within the two-hour period after
taking ofloxacin (See Drug Interactions);
- that ofloxacin can be taken without regard to meals;
- that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that
patients should know how they react to ofloxacin before they operate an automobile or machinery or
engage in activities requiring mental alertness and coordination
- to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture
of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture
has been confidently excluded;
- that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to
discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat,
difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips,
tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction
- to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue
therapy if phototoxicity (e. g. , skin eruption) occurs;
- that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue
ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician
- that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their
physician before taking this drug if there is a history of this condition.
Fugacin
Atto interessato organismi
Batteri enterici e altri eubatteri